Medline ® Abstract for Reference 74
of 'Management of acute chemotherapy-related diarrhea'
Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.
Harris AG, O'Dorisio TM, Woltering EA, Anthony LB, Burton FR, Geller RB, Grendell JH, Levin B, Redfern JS
Dig Dis Sci. 1995;40(7):1464.
Octreotide is an effective therapeutic option in controlling secretory diarrhea of varied etiology. However, marked patient-to-patient differences in the antidiarrheal effects necessitate titration of octreotide dose in individual patients to achieve optimal symptom control. A consensus development panel established guidelines for octreotide dose titration in patients with secretory diarrhea. Overall, the panel recommended an aggressive approach in selecting the initial octreotide dose and in making subsequent dose escalations in patients with secretory diarrhea due to gastrointestinal tumors (eg, carcinoids, VIPomas), AIDS, dumping syndrome, short bowel syndrome, radiotherapy, or chemotherapy. To avoid hypoglycemia in patients with diabetes mellitus-associated secretory diarrhea, the panel recommended a low initial octreotide dose and a conservative titration regimen with close monitoring a blood glucose levels. The end point of therapy should focus on a reduction in diarrhea (frequency of bowel movements or stool volume) rather than normalization of hormonal profile. Overall, octreotide is well tolerated; principal side effects are transient injection site pain and gastrointestinal discomfort. For many patients with secretory diarrhea, octreotide therapy is expected to improve the overall health and quality of life and in the long run will lessen health care costs.
Division of Endocrinology and Metabolism, Ohio State University College of Medicine, Columbus 43210-1228, USA.